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“Prolonged Administration of the Kappa Opioid Receptor
Agonist Difelikefalin Retains Diuretic Efficacy”
Ashlyn Y. Anderson, Luke E. Beckendorf, Daniel R. Kapusta, Ph.D.
LSUHSC Department of Pharmacology and Experimental Therapeutics
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Methods
 12 male Sprague-Dawley rats
were weight-matched and
separated into two groups:
Treatment difelikefalin (n=6; 20 ug/mL, 20
ug/kg, i.p.) or vehicle (n=6,
Groups
isotonic saline, i.p.) and treated
twice daily for 10 days.
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Prolonged use of the loop diuretic furosemide in
the treatment of congestive heart failure is
associated with potential adverse effects including
hyponatremia, hypokalemia, and diuretic resistance.
The kappa opioid receptor (KOR) agonist
difelikefalin produces a sodium sparing diuresis by
inhibiting hypothalamic neurons responsible for the
secretion/release of antidiuretic hormone (ADH) in
the paraventricular nucleus (PVN).
Our lab has shown that acute administration of
difelikefalin produces a sodium-sparing diuresis
both alone and in conjunction with the loop-diuretic
furosemide.
We hypothesize that prolonged
administration of difelikefalin will retain its
diuretic efficacy over time and avoid the
development of diuretic resistance.
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Figure 2. Gα subunit protein levels in the
hypothalamic paraventricular nucleus (PVN). Rats
treated twice per day with difelikefalin (D) or saline (S)
for 10 days (n = 3 per group). Representative Western
blots illustrating Gαq, Gαi2, or Gαz protein levels with
tubulin used as a loading control.

Summary of Results

10-Day Cumulative
24-hr H2O Intake

 H2O intake and 5-hr urine output
were measured daily after the first
injection using metabolic cages.
Data  Rats were sacrificed on day 10
Collection and harvested brains were frozen
at -80°C.
 PVN tissue was collected using a
1-mm2 punch on the cryostat.
 Gαq, Gαz, and Gαi2 subunit
protein levels were determined in
PVN tissue via Western blot.
Post-Study  Statistical analyses of all data
Analysis were performed using a 2-way
ANOVA on GraphPad Prism 9.4.0
(673).

PVN

 Difelikefalin treatment produced a marked diuretic
response that was maintained over 10 days of treatment
as compared to vehicle treated rats.
 There were no significant differences in water intake,
urinary sodium excretion (UNaV), or weight between
the two groups. However, difelikefalin significantly
decreased urinary potassium excretion (UKV).
 No change in the PVN Gαq, Gαz, or Gαi2 subunit
protein levels was found between the difelikefalin and
control groups.

Significance

Figure 1. Effects of prolonged difelikefalin treatment on
1A) daily 5-hr urine output, 1B) 10-day cumulative
urinary sodium/potassium excretion, and 1C) water
intake. A) 5-hr urine was collected from rats treated twice
daily with difelikefalin (n=6; 20 μg/kg, i.p) or vehicle (n=6;
i.p.) for 10 days then B) analyzed for sodium (UNaV) or
potassium (UKV) excretion. C) 5-hr and 24-hr water intake
was measured between the groups.

These findings showed that the kappa agonist,
difelikefalin, produces a marked and sustained water
diuresis over 10 days. Since kappa opioids inhibit the
central release of ADH, it is likely that the combined
administration of difelikefalin and a loop diuretic
(furosemide) may offer a novel approach to treat
edematous patients without causing diuretic resistance or
excessive loss of sodium or potassium.
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